#Sweden #Stockholm #Shareholder #Biopharma #Sobi

Sobi Updates Shareholder Information

On September 30, 2025, Swedish Orphan Biovitrum AB (commonly known as Sobi) disclosed its latest shareholder information, revealing that the total count of shares has reached an impressive 357,412,837. This figure comprises entirely common shares, further emphasizing the company's commitment to transparency and corporate governance.

Conversion of Class C Shares

The recent changes in Sobi's share structure are primarily due to the conversion of 1,412,788 Class C shares into common shares. This process aimed to ensure the fulfillment of obligations under long-term incentive programs, a strategic move designed to align the interests of shareholders and management. The Class C shares were initially issued specifically for this purpose. Following the conversion, the total number of voting rights has also increased to 357,412,837, matching the total number of common shares.

Current Holdings

As it stands on September 30, 2025, Sobi holds 12,756,537 common shares in treasury. This ownership demonstrates Sobi's strategic management of its capital structure, providing flexibility for future decisions related to share distribution and investor relations.

Company Overview

Founded to address the needs of patients living with rare diseases, Sobi has established itself as a leading global biopharmaceutical company. With nearly 1,900 employees spread across various continents—Europe, North America, the Middle East, Asia, and Australia—Sobi is dedicated to fortifying its position within the biopharmaceutical industry. In 2024, the company reported a robust revenue of 26 billion SEK, showcasing its impactful contributions to healthcare.

Market Presence and Future Directions

Sobi's shares are presently traded on Nasdaq Stockholm (STO SOBI), which underscores its commitment to maintaining robust investor engagement and capital market presence. As the company continues to innovate and expand its product offerings, it remains focused on improving the quality of life for individuals with rare diseases.

As a progressive company, Sobi invests in research and development, working tirelessly to unlock the potential of breakthrough innovations. For more information about Sobi's initiatives, upcoming projects, and detailed investor relations, interested parties can visit sobi.com and follow their updates on LinkedIn.

In conclusion, Sobi's latest share and voting update reflects a promising trajectory for the company as it navigates the complexities of the biopharmaceutical landscape. Their proactive approach to shareholder engagement and commitment to innovation positions Sobi for continued success in the years to come.

Contact Information

For inquiries related to Sobi's investor relations, please reach out to Gerard Tobin, Head of Investor Relations. This information was provided in accordance with the Swedish Financial Instruments Trading Act, ensuring compliance with regulatory standards.

This announcement was made public on September 30, 2025, at 08:00 CEST, and reflects Sobi's dedication to maintaining a responsible and transparent flow of information for its shareholders.